Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Net Cash Flow: 2014-2024

Historic Net Cash Flow for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to -$89.5 million.

  • Protagonist Therapeutics' Net Cash Flow rose 75.58% to -$54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year increase of 82.55%. This contributed to the annual value of -$89.5 million for FY2024, which is 246.73% down from last year.
  • As of FY2024, Protagonist Therapeutics' Net Cash Flow stood at -$89.5 million, which was down 246.73% from $61.0 million recorded in FY2023.
  • Over the past 5 years, Protagonist Therapeutics' Net Cash Flow peaked at $84.2 million during FY2020, and registered a low of -$89.5 million during FY2024.
  • In the last 3 years, Protagonist Therapeutics' Net Cash Flow had a median value of $2.2 million in 2022 and averaged -$8.8 million.
  • Per our database at Business Quant, Protagonist Therapeutics' Net Cash Flow skyrocketed by 2,711.57% in 2023 and then plummeted by 246.73% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Net Cash Flow (Yearly) stood at $84.2 million in 2020, then tumbled by 92.64% to $6.2 million in 2021, then crashed by 65.00% to $2.2 million in 2022, then spiked by 2,711.57% to $61.0 million in 2023, then plummeted by 246.73% to -$89.5 million in 2024.